70 participants
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-18
- Start Date:
- 2026-03-13
- Completion:
- 2027-12-31
Conditions
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
Interventions
- DRUG
No Results Yet